Skip to main content
SpringerLink
Log in

Novavax COVID-19 vaccine: no new safety concerns

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Romanson B, et al. Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years - United States, July 13, 2022-March 13, 2023. Morbidity and Mortality Weekly Report 72: 850-851, No. 31, et al. Aug 2023. Available from: URL: http://doi.org/10.15585/mmwr.mm7231a4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Novavax COVID-19 vaccine: no new safety concerns. Reactions Weekly 1971, 10 (2023). https://doi.org/10.1007/s40278-023-45135-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-45135-2

Search

Navigation